170 related articles for article (PubMed ID: 25640878)
1. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities.
Poty S; Désogère P; Goze C; Boschetti F; D'huys T; Schols D; Cawthorne C; Archibald SJ; Maëcke HR; Denat F
Dalton Trans; 2015 Mar; 44(11):5004-16. PubMed ID: 25640878
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
Van Hout A; D'huys T; Oeyen M; Schols D; Van Loy T
PLoS One; 2017; 12(4):e0176057. PubMed ID: 28410420
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands.
Sakyiamah MM; Kobayakawa T; Fujino M; Konno M; Narumi T; Tanaka T; Nomura W; Yamamoto N; Murakami T; Tamamura H
Bioorg Med Chem; 2019 Mar; 27(6):1130-1138. PubMed ID: 30772128
[TBL] [Abstract][Full Text] [Related]
4. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.
Jacobson O; Weiss ID; Szajek L; Farber JM; Kiesewetter DO
Bioorg Med Chem; 2009 Feb; 17(4):1486-93. PubMed ID: 19188071
[TBL] [Abstract][Full Text] [Related]
5. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.
Arakaki R; Tamamura H; Premanathan M; Kanbara K; Ramanan S; Mochizuki K; Baba M; Fujii N; Nakashima H
J Virol; 1999 Feb; 73(2):1719-23. PubMed ID: 9882387
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a fluorescent derivative of AMD3100 and its interaction with the CXCR4 chemokine receptor.
Knight JC; Hallett AJ; Brancale A; Paisey SJ; Clarkson RW; Edwards PG
Chembiochem; 2011 Nov; 12(17):2692-8. PubMed ID: 21998043
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
Bridger GJ; Skerlj RT; Padmanabhan S; Martellucci SA; Henson GW; Struyf S; Witvrouw M; Schols D; De Clercq E
J Med Chem; 1999 Sep; 42(19):3971-81. PubMed ID: 10508445
[TBL] [Abstract][Full Text] [Related]
8. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
Princen K; Hatse S; Vermeire K; Bridger GJ; Skerlj RT; De Clercq E; Schols D
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1135-9. PubMed ID: 14709250
[TBL] [Abstract][Full Text] [Related]
9. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
Cabrera C; Gutiérrez A; Blanco J; Barretina J; Litovchick A; Lapidot A; Evdokimov AG; Clotet B; Esté JA
AIDS Res Hum Retroviruses; 2000 May; 16(7):627-34. PubMed ID: 10791873
[TBL] [Abstract][Full Text] [Related]
10. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.
Khan A; Greenman J; Archibald SJ
Curr Med Chem; 2007; 14(21):2257-77. PubMed ID: 17896975
[TBL] [Abstract][Full Text] [Related]
11. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
Hatse S; Princen K; Gerlach LO; Bridger G; Henson G; De Clercq E; Schwartz TW; Schols D
Mol Pharmacol; 2001 Jul; 60(1):164-73. PubMed ID: 11408611
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor.
Rosenkilde MM; Gerlach LO; Jakobsen JS; Skerlj RT; Bridger GJ; Schwartz TW
J Biol Chem; 2004 Jan; 279(4):3033-41. PubMed ID: 14585837
[TBL] [Abstract][Full Text] [Related]
13. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.
De Clercq E
Mini Rev Med Chem; 2005 Sep; 5(9):805-24. PubMed ID: 16178723
[TBL] [Abstract][Full Text] [Related]
14. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.
Gerlach LO; Skerlj RT; Bridger GJ; Schwartz TW
J Biol Chem; 2001 Apr; 276(17):14153-60. PubMed ID: 11154697
[TBL] [Abstract][Full Text] [Related]
15. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Donzella GA; Schols D; Lin SW; Esté JA; Nagashima KA; Maddon PJ; Allaway GP; Sakmar TP; Henson G; De Clercq E; Moore JP
Nat Med; 1998 Jan; 4(1):72-7. PubMed ID: 9427609
[TBL] [Abstract][Full Text] [Related]
16. The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity.
Huskens D; Princen K; Schreiber M; Schols D
Virology; 2007 Jul; 363(2):280-7. PubMed ID: 17331556
[TBL] [Abstract][Full Text] [Related]
17. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.
Hatse S; Princen K; Bridger G; De Clercq E; Schols D
FEBS Lett; 2002 Sep; 527(1-3):255-62. PubMed ID: 12220670
[TBL] [Abstract][Full Text] [Related]
18. CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.
Klasse PJ; Rosenkilde MM; Signoret N; Pelchen-Matthews A; Schwartz TW; Marsh M
J Virol; 1999 Sep; 73(9):7453-66. PubMed ID: 10438835
[TBL] [Abstract][Full Text] [Related]
19. NeoR6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity.
Lapidot A; Peled A; Berchanski A; Pal B; Kollet O; Lapidot T; Borkow G
Biochim Biophys Acta; 2008 Jun; 1780(6):914-20. PubMed ID: 18410746
[TBL] [Abstract][Full Text] [Related]
20. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
